Zeo ScientifiX Inc (ZEOX)

[Buellersback]

Wow, so much potential!

Organicell Regenerative Medicine
UNITED STATESUnited States
Post An EnquiryPost An Enquiry
Virtual BoothVirtual Booth
ARVO 2021
Participation Not Confirmed
Update your events
Organicell's Zofin™ Featured in Two National Publications Examining Potential Therapies for COVID-19 Long-Haulers
Contact the Supplier
Lead Product(s): Zofin
Therapeutic Area: Pulmonary/Respiratory DiseasesProduct Name: Zofin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableDecember 29, 2020
Details:
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.
Organicell Regenerative Medicine
Deals
Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Organicell Regenerative Medicine
UNITED STATESUnited States
Post An EnquiryPost An Enquiry
Virtual BoothVirtual Booth
ARVO 2021
Participation Not Confirmed
Update your events
Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure
Contact the Supplier
Lead Product(s): Zofin
Therapeutic Area: Cardiology/Vascular DiseasesProduct Name: Zofin
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Regenerative Care Network
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: PartnershipOctober 20, 2020
Details:
Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.
Organicell Regenerative Medicine
Development Update
Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Organicell Regenerative Medicine
UNITED STATESUnited States
Post An EnquiryPost An Enquiry
Virtual BoothVirtual Booth
ARVO 2021
Participation Not Confirmed
Update your events
FDA Grants Organicell Expanded Access To Treat COVID-19 Patients With ZofinTM
Contact the Supplier
Lead Product(s): Zofin
Therapeutic Area: Infections and Infectious DiseasesProduct Name: Zofin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableSeptember 29, 2020
Details:
Aside from Convalescent Plasma, Zofin, is the first reported acellular therapy which can be accessed under FDA’s approved expanded access program.
Organicell Regenerative Medicine
Deals
Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Organicell Regenerative Medicine
UNITED STATESUnited States
Post An EnquiryPost An Enquiry
Virtual BoothVirtual Booth
ARVO 2021
Participation Not Confirmed
Update your events
Organicell Partnered With Alternative Research Associates
Contact the Supplier
Lead Product(s): Zofin
Therapeutic Area: Infections and Infectious DiseasesProduct Name: Zofin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: Alternative Research Associates
Deal Size: UndisclosedUpfront Cash: Undisclosed
Deal Type: PartnershipAugust 18, 2020
Details:
The objective of the FDA phase I/II study is to investigate the safety and potential efficacy of perinatal sourced components for COVID-19. The study will enroll 20 patients and is expected to commence within the next two weeks.
Organicell Regenerative Medicine
Development Update
Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Organicell Regenerative Medicine
UNITED STATESUnited States
Post An EnquiryPost An Enquiry
Virtual BoothVirtual Booth
ARVO 2021
Participation Not Confirmed
Update your events
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
Contact the Supplier
Lead Product(s): Organicell Flow
Therapeutic Area: Infections and Infectious DiseasesProduct Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMay 27, 2020
Details:
Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data.
Organicell Regenerative Medicine
Development Update
Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Organicell Regenerative Medicine
UNITED STATESUnited States
Post An EnquiryPost An Enquiry
Virtual BoothVirtual Booth
ARVO 2021
Participation Not Confirmed
Update your events
Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19
Contact the Supplier
Lead Product(s): Organicell Flow
Therapeutic Area: Pulmonary/Respiratory DiseasesProduct Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not ApplicableUpfront Cash: Not Applicable
Deal Type: Not ApplicableMay 05, 2020
Details:
This trial will be the first randomized, double-blinded, placebo-controlled, phase I/II multi-center trial investigating the safety and efficacy of amniotic fluid sourced components for COVID-19.